Patient Safety Organizations: Voluntary Relinquishment for the Institute for Safe Medication Practices (ISMP), 53003-53004 [2020-18877]

Download as PDF Federal Register / Vol. 85, No. 167 / Thursday, August 27, 2020 / Notices A. Purpose GENERAL SERVICES ADMINISTRATION [OMB Control No. 3090–0250; Docket No. 2020–0001; Sequence No. 7] Information Collection; General Services Administration Acquisition Regulation; Zero Burden Information Collection Reports Office of the Chief Acquisition Officer, General Services Administration (GSA). ACTION: Notice of request for public comments regarding an extension to an existing OMB information collection. AGENCY: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division (MVCB) will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a previously approved information collection requirement regarding Zero Burden Information Collection Reports. DATES: Submit comments on or before: October 26, 2020. ADDRESSES: Submit comments identified by Information Collection 3090–0250, Zero Burden Information Collection Reports via http:// www.regulations.gov. Submit comments via the Federal eRulemaking portal by searching the OMB control number 3090–0250. Select the link ‘‘Comment Now’’ that corresponds with ‘‘Information Collection 3090–0250, Zero Burden Information Collection Reports’’. Follow the instructions provided on the screen. Please include your name, company name (if any), and ‘‘Information Collection 3090–0250, Zero Burden Information Collection Reports’’ on your attached document. Instructions: Please submit comments only and cite Information Collection 3090–0250, Zero Burden Information Collection Reports, in all correspondence related to this collection. Comments received generally will be posted without change to regulations.gov, including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check regulations.gov, approximately two-to-three days after submission to verify posting. FOR FURTHER INFORMATION CONTACT: Mr. Thomas O’Linn, Procurement Analyst, General Services Acquisition Policy, at 202–445–0390 or via email at Thomas.olinn@gsa.gov. SUPPLEMENTARY INFORMATION: khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:09 Aug 26, 2020 Jkt 250001 This information requirement consists of reports that do not impose collection burdens upon the public. These collections require information which is already available to the public at large, or that is routinely exchanged by firms during the normal course of business. A general control number for these collections decreases the amount of paperwork generated by the approval process. Under clause 552.238–73, ‘‘Identification of Electronic Office Equipment Providing Accessibility for the Handicapped,’’ (previous clause number 552.238–70) the offeror is encouraged to identify office equipment, including any special peripheral that will facilitate electronic office equipment accessibility for handicapped individuals in its commercial catalogs and pricelists accepted by the Government. B. Annual Reporting Burden None. C. Public Comments Public comments are particularly invited on: Whether this collection of information is necessary and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate and based on valid assumptions and methodology; and ways to enhance the quality, utility, and clarity of the information to be collected. Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405, telephone 202–501–4755. Please cite OMB Control No. 3090– 0250, Zero Burden Information Collection Reports, in all correspondence. Jeffrey A. Koses, Senior Procurement Executive, Office of Acquisition Policy, Office of Governmentwide Policy. [FR Doc. 2020–18799 Filed 8–26–20; 8:45 am] BILLING CODE 6820–61–P PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 53003 DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality Patient Safety Organizations: Voluntary Relinquishment for the Institute for Safe Medication Practices (ISMP) Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services (HHS). ACTION: Notice of delisting. AGENCY: The Patient Safety and Quality Improvement Final Rule (Patient Safety Rule) authorizes AHRQ, on behalf of the Secretary of HHS, to list as a patient safety organization (PSO) an entity that attests that it meets the statutory and regulatory requirements for listing. A PSO can be ‘‘delisted’’ by the Secretary if it is found to no longer meet the requirements of the Patient Safety and Quality Improvement Act of 2005 (Patient Safety Act) and Patient Safety Rule, when a PSO chooses to voluntarily relinquish its status as a PSO for any reason, or when a PSO’s listing expires. AHRQ accepted a notification of proposed voluntary relinquishment from the Institute for Safe Medication Practices (ISMP), PSO number P0009, of its status as a PSO, and has delisted the PSO accordingly. DATES: The delisting was effective at 12:00 Midnight ET (2400) on August 17, 2020. ADDRESSES: The directories for both listed and delisted PSOs are ongoing and reviewed weekly by AHRQ. Both directories can be accessed electronically at the following HHS website: http://www.pso.ahrq.gov/listed. FOR FURTHER INFORMATION CONTACT: Cathryn Bach, Center for Quality Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, MS 06N100B, Rockville, MD 20857; Telephone (toll free): (866) 403–3697; Telephone (local): (301) 427–1111; TTY (toll free): (866) 438–7231; TTY (local): (301) 427–1130; Email: pso@ahrq.hhs.gov. SUPPLEMENTARY INFORMATION: SUMMARY: Background The Patient Safety Act, 42 U.S.C. 299b–21 to 299b–26, and the related Patient Safety Rule, 42 CFR part 3, published in the Federal Register on November 21, 2008 (73 FR 70732– 70814), establish a framework by which individuals and entities that meet the definition of provider in the Patient Safety Rule may voluntarily report information to PSOs listed by AHRQ, on a privileged and confidential basis, for E:\FR\FM\27AUN1.SGM 27AUN1 53004 Federal Register / Vol. 85, No. 167 / Thursday, August 27, 2020 / Notices khammond on DSKJM1Z7X2PROD with NOTICES the aggregation and analysis of patient safety events. The Patient Safety Act authorizes the listing of PSOs, which are entities or component organizations whose mission and primary activity are to conduct activities to improve patient safety and the quality of health care delivery. HHS issued the Patient Safety Rule to implement the Patient Safety Act. AHRQ administers the provisions of the Patient Safety Act and Patient Safety Rule relating to the listing and operation of PSOs. The Patient Safety Rule authorizes AHRQ to list as a PSO an entity that attests that it meets the statutory and regulatory requirements for listing. A PSO can be ‘‘delisted’’ if it is found to no longer meet the requirements of the Patient Safety Act and Patient Safety Rule, when a PSO chooses to voluntarily relinquish its status as a PSO for any reason, or when a PSO’s listing expires. Section 3.108(d) of the Patient Safety Rule requires AHRQ to provide public notice when it removes an organization from the list of PSOs. AHRQ has accepted a notification of proposed voluntary relinquishment from the Institute for Safe Medication Practices (ISMP) to voluntarily relinquish its status as a PSO. Accordingly, the Institute for Safe Medication Practices (ISMP), P0009, was delisted effective at 12:00 Midnight ET (2400) on August 17, 2020. Institute for Safe Medication Practices (ISMP) has patient safety work product (PSWP) in its possession. The PSO will meet the requirements of section 3.108(c)(2)(i) of the Patient Safety Rule regarding notification to providers that have reported to the PSO and of section 3.108(c)(2)(ii) regarding disposition of PSWP consistent with section 3.108(b)(3). According to section 3.108(b)(3) of the Patient Safety Rule, the PSO has 90 days from the effective date of delisting and revocation to complete the disposition of PSWP that is currently in the PSO’s possession. More information on PSOs can be obtained through AHRQ’s PSO website at http://www.pso.ahrq.gov. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2020–0088] Privacy Act of 1974; System of Records Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of a new system of records. AGENCY: Virginia L. Mackay-Smith, Associate Director. In accordance with the requirements of the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS) is establishing a new system of records to be maintained by the Centers for Disease Control and Prevention, 09–20–0180, ‘‘Electronic Import Permit Program Portal (eIPP Portal).’’ The system of records will be used by CDC to monitor the importation of infectious biological agents, infectious substances, and vectors of human disease. DATES: The modified system of records is applicable August 27, 2020, subject to a 30-day period in which to comment on the routine uses. Written comments must be received on or before September 28, 2020. ADDRESSES: You may submit comments, identified by Docket No. CDC–2020– 0088 by any of the following methods: • Federal eRulemaking Portal: http:// www.regulations.gov. Follow the instructions for submitting comments. • Mail: Beverly Walker, Chief Privacy Officer, CDC Privacy Unit, CyberSecurity Program Office (CSPO), Centers for Disease Control and Prevention, 4770 Buford Hwy., Mailstop S101, Atlanta, GA 30341. Instructions: All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to https://regulations.gov, including any personal information provided. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. For access to the docket to read background documents or comments received, go to https:// www.regulations.gov. [FR Doc. 2020–18877 Filed 8–26–20; 8:45 am] FOR FURTHER INFORMATION CONTACT: BILLING CODE 4160–90–P Beverly Walker, Chief Privacy Officer, CDC Privacy Unit, CyberSecurity Program Office (CSPO), Centers for Disease Control and Prevention, 4770 Buford Hwy., Mailstop S101, Atlanta, GA 30341. Telephone: 770–488–8524. VerDate Sep<11>2014 17:09 Aug 26, 2020 Jkt 250001 SUMMARY: PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 SUPPLEMENTARY INFORMATION: I. Background on the CDC Import Permit Program Under the authority of Section 361 of the Public Health Service Act (PHS Act) (42 U.S.C. 264), the HHS Secretary makes and enforces such regulations as in his/her judgment are necessary to prevent the introduction, transmission, or spread of communicable diseases from foreign countries into the U.S. states or territories. For purposes of carrying out and enforcing such regulations, the HHS Secretary may authorize a variety of public health measures, including inspection, fumigation, disinfection, sanitation, pest extermination, destruction of animals or articles found to be sources of dangerous infection to human beings, and other measures. The Foreign Quarantine regulations (42 CFR part 71) set forth provisions to prevent the introduction, transmission, and spread of communicable disease from foreign countries into the United States. Part 71, Subpart F (Importations) contains provisions governing the importation of infectious biological agents, infectious substances, and vectors (42 CFR 71.54), including requiring persons to obtain a permit issued by the CDC before importing, or distributing after import, any of these materials. The purpose of the import permit requirement and permitting process is to prevent the introduction, transmission, or spread of communicable diseases from foreign countries into the U.S. states or territories. Before issuing an import permit, the CDC Division of Select Agents and Toxins, Import Permit Program (CDC/IPP) reviews the application to ensure the applicant has appropriate safety measures in place for importing and working safely with the applicable infectious biological agent(s), substance(s), and/or vector(s). Regulations of the U.S. Department of Transportation apply to such materials while in transit in the U.S. states and territories. II. New System of Records 09–20–0180 The proposed new system of records, ‘‘Electronic Import Permit Program Portal (eIPP Portal),’’ will cover records about individual applicants, which the CDC/IPP maintains in the new eIPP Portal information technology (IT) system for the purpose of overseeing— and issuing permits allowing—the importation of infectious biological agents, infectious substances, and vectors of human disease as outlined in the import permit regulations at 42 CFR 71.54. The eIPP Portal IT system is a single web-based information E:\FR\FM\27AUN1.SGM 27AUN1

Agencies

[Federal Register Volume 85, Number 167 (Thursday, August 27, 2020)]
[Notices]
[Pages 53003-53004]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18877]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Patient Safety Organizations: Voluntary Relinquishment for the 
Institute for Safe Medication Practices (ISMP)

AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department 
of Health and Human Services (HHS).

ACTION: Notice of delisting.

-----------------------------------------------------------------------

SUMMARY: The Patient Safety and Quality Improvement Final Rule (Patient 
Safety Rule) authorizes AHRQ, on behalf of the Secretary of HHS, to 
list as a patient safety organization (PSO) an entity that attests that 
it meets the statutory and regulatory requirements for listing. A PSO 
can be ``delisted'' by the Secretary if it is found to no longer meet 
the requirements of the Patient Safety and Quality Improvement Act of 
2005 (Patient Safety Act) and Patient Safety Rule, when a PSO chooses 
to voluntarily relinquish its status as a PSO for any reason, or when a 
PSO's listing expires. AHRQ accepted a notification of proposed 
voluntary relinquishment from the Institute for Safe Medication 
Practices (ISMP), PSO number P0009, of its status as a PSO, and has 
delisted the PSO accordingly.

DATES: The delisting was effective at 12:00 Midnight ET (2400) on 
August 17, 2020.

ADDRESSES: The directories for both listed and delisted PSOs are 
ongoing and reviewed weekly by AHRQ. Both directories can be accessed 
electronically at the following HHS website: http://www.pso.ahrq.gov/listed.

FOR FURTHER INFORMATION CONTACT: Cathryn Bach, Center for Quality 
Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, MS 06N100B, 
Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone 
(local): (301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local): 
(301) 427-1130; Email: [email protected].

SUPPLEMENTARY INFORMATION:

Background

    The Patient Safety Act, 42 U.S.C. 299b-21 to 299b-26, and the 
related Patient Safety Rule, 42 CFR part 3, published in the Federal 
Register on November 21, 2008 (73 FR 70732-70814), establish a 
framework by which individuals and entities that meet the definition of 
provider in the Patient Safety Rule may voluntarily report information 
to PSOs listed by AHRQ, on a privileged and confidential basis, for

[[Page 53004]]

the aggregation and analysis of patient safety events.
    The Patient Safety Act authorizes the listing of PSOs, which are 
entities or component organizations whose mission and primary activity 
are to conduct activities to improve patient safety and the quality of 
health care delivery. HHS issued the Patient Safety Rule to implement 
the Patient Safety Act. AHRQ administers the provisions of the Patient 
Safety Act and Patient Safety Rule relating to the listing and 
operation of PSOs. The Patient Safety Rule authorizes AHRQ to list as a 
PSO an entity that attests that it meets the statutory and regulatory 
requirements for listing. A PSO can be ``delisted'' if it is found to 
no longer meet the requirements of the Patient Safety Act and Patient 
Safety Rule, when a PSO chooses to voluntarily relinquish its status as 
a PSO for any reason, or when a PSO's listing expires. Section 3.108(d) 
of the Patient Safety Rule requires AHRQ to provide public notice when 
it removes an organization from the list of PSOs.
    AHRQ has accepted a notification of proposed voluntary 
relinquishment from the Institute for Safe Medication Practices (ISMP) 
to voluntarily relinquish its status as a PSO. Accordingly, the 
Institute for Safe Medication Practices (ISMP), P0009, was delisted 
effective at 12:00 Midnight ET (2400) on August 17, 2020. Institute for 
Safe Medication Practices (ISMP) has patient safety work product (PSWP) 
in its possession. The PSO will meet the requirements of section 
3.108(c)(2)(i) of the Patient Safety Rule regarding notification to 
providers that have reported to the PSO and of section 3.108(c)(2)(ii) 
regarding disposition of PSWP consistent with section 3.108(b)(3). 
According to section 3.108(b)(3) of the Patient Safety Rule, the PSO 
has 90 days from the effective date of delisting and revocation to 
complete the disposition of PSWP that is currently in the PSO's 
possession.
    More information on PSOs can be obtained through AHRQ's PSO website 
at http://www.pso.ahrq.gov.

Virginia L. Mackay-Smith,
Associate Director.
[FR Doc. 2020-18877 Filed 8-26-20; 8:45 am]
BILLING CODE 4160-90-P